SG Americas Securities
ELVN icon

SG Americas Securities’s Enliven Therapeutics ELVN Stock Holding History

SG Americas Securities’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Buy
+10,751
New +$456K ﹤0.01% 2265
2026
Q1 		– Sell
-14,035
Closed -$216K – 3367
2025
Q4 		$216K Sell
14,035
-8,207
-37% -$163K ﹤0.01% 2893
2025
Q3 		$455K Sell
22,242
-14,131
-39% -$285K ﹤0.01% 2192
2025
Q2 		$730K Buy
36,373
+23,261
+177% +$440K ﹤0.01% 1383
2025
Q1 		$258K Sell
13,112
-3,517
-21% -$75.7K ﹤0.01% 2339
2024
Q4 		$374K Buy
16,629
+6,616
+66% +$172K ﹤0.01% 1605
2024
Q3 		$256K Buy
+10,013
New +$232K ﹤0.01% 2282
2024
Q2 		– Sell
-9,430
Closed -$166K – 2969
2024
Q1 		$166K Sell
9,430
-4,071
-30% -$62.5K ﹤0.01% 2116
2023
Q4 		$187K Buy
13,501
+2,041
+18% +$25K ﹤0.01% 2225
2023
Q3 		$157K Buy
+11,460
New +$193K ﹤0.01% 2465
2020
Q4 		– Sell
-1,642
Closed -$134K – 3366
2020
Q3 		$134K Buy
+1,642
New +$148K ﹤0.01% 2334

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

SG Americas Securities's ELVN Position: Q2 2026 in Review

SG Americas Securities opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 10,751 shares worth $546K. The stake represents ﹤0.01% of the portfolio and ranks #2265 among its holdings. This is a return to the name: SG Americas Securities previously reported a position in ELVN as recently as Q4 2025.

SG Americas Securities first reported a position in ELVN in Q3 2020 and has held it in 11 quarters since. The position peaked at $730K in Q2 2025. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • SG Americas Securities held 10,751 shares of Enliven Therapeutics worth $546K as of Q2 2026.
  • Enliven Therapeutics was a new SG Americas Securities position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2265 holding.
  • SG Americas Securities first reported a position in Enliven Therapeutics in Q3 2020 and has held it in 11 quarters since.
  • SG Americas Securities's Enliven Therapeutics position peaked at $730K in Q2 2025.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.